- Home
- COMM vs AUPH Comparison
COMM vs AUPH Comparison
Compare COMM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMM
- AUPH
- Stock Information
- Founded
- COMM 1976
- AUPH 1993
- Country
- COMM United States
- AUPH Canada
- Employees
- COMM N/A
- AUPH N/A
- Industry
- COMM Radio And Television Broadcasting And Communications Equipment
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- COMM Technology
- AUPH Health Care
- Exchange
- COMM Nasdaq
- AUPH Nasdaq
- Market Cap
- COMM 1.3B
- AUPH 1.1B
- IPO Year
- COMM 2013
- AUPH 1999
- Fundamental
- Price
- COMM $8.65
- AUPH $7.58
- Analyst Decision
- COMM Hold
- AUPH Strong Buy
- Analyst Count
- COMM 4
- AUPH 2
- Target Price
- COMM $4.88
- AUPH $11.50
- AVG Volume (30 Days)
- COMM 5.7M
- AUPH 1.6M
- Earning Date
- COMM 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- COMM N/A
- AUPH N/A
- EPS Growth
- COMM N/A
- AUPH N/A
- EPS
- COMM 3.42
- AUPH 0.27
- Revenue
- COMM $4,417,100,000.00
- AUPH $247,295,000.00
- Revenue This Year
- COMM $21.50
- AUPH $12.15
- Revenue Next Year
- COMM $8.30
- AUPH $18.31
- P/E Ratio
- COMM $2.55
- AUPH $28.53
- Revenue Growth
- COMM 16.19
- AUPH 29.20
- 52 Week Low
- COMM $1.05
- AUPH $5.20
- 52 Week High
- COMM $8.67
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- COMM 80.64
- AUPH 40.36
- Support Level
- COMM $7.91
- AUPH $7.29
- Resistance Level
- COMM $8.58
- AUPH $8.86
- Average True Range (ATR)
- COMM 0.41
- AUPH 0.34
- MACD
- COMM 0.18
- AUPH -0.06
- Stochastic Oscillator
- COMM 100.00
- AUPH 19.37
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.